Publication: Synthesis and structure-activity relationship of mono-indole-, bis-indole-, and tris-indole-based sulfonamides as potential anticancer agents
| dc.contributor.author | Pingaew R. | |
| dc.contributor.author | Prachayasittikul S. | |
| dc.contributor.author | Ruchirawat S. | |
| dc.contributor.author | Prachayasittikul V. | |
| dc.date.accessioned | 2021-04-05T03:32:52Z | |
| dc.date.available | 2021-04-05T03:32:52Z | |
| dc.date.issued | 2013 | |
| dc.date.issuedBE | 2556 | |
| dc.description.abstract | A series of arylsulfonyl mono-indoles (10-15), bis-indoles (16-27), and tris-indoles (28-32) have been synthesized and evaluated for their cytotoxicity toward four human cancer cell lines including HuCCA-1 (cholangiocarcinoma), HepG2 (hepatocellular carcinoma), A-549 (lung carcinoma), and MOLT-3 (lymphoblastic leukemia). Most of the synthesized indoles displayed cytotoxicity against the MOLT-3 cell line except for analogs 16, 17, and 32. Significantly, the NN -sulfonylphenolic bis-indole series (18-27) and the NN -chlorobenzenesulfonyl tris-indole (30) showed higher antiproliferative activity against HepG2 cell than the reference drug, etoposide. Promisingly, the NN -chlorobenzenesulfonyl bis-indole (20) and tris-indole (30) provided 3-fold and 2-fold stronger activity, respectively, against HepG2 cell than etoposide. Moreover, the phenolic bis-indole (20) was also shown to be the most potent cytotoxic agent against HuCCA-1 and A-549 cell lines with IC50 values of 7.75 and 8.74 μ M, respectively. The tris-indole analogs 28, 29, and 31 also exhibited selectivity against MOLT-3 cell. The findings disclosed that NN -arylsulfonyl bis-indoles-bearing phenolic groups are potentially interesting lead pharmacophores of anticancer agents that should be further investigated in more detail. © 2013 Springer Science+Business Media Dordrecht. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Molecular Diversity. Vol 17, No.3 (2013), p.595-604 | |
| dc.identifier.doi | 10.1007/s11030-013-9457-7 | |
| dc.identifier.issn | 13811991 | |
| dc.identifier.other | 2-s2.0-84880829458 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/6601 | |
| dc.rights.holder | มหาวิทยาลัยศรีนครินทรวิโรฒ | |
| dc.subject.other | Antineoplastic agent | |
| dc.subject.other | Sulfonamide | |
| dc.subject.other | Sulfonyl bis indole derivative | |
| dc.subject.other | Sulfonyl mono indole derivative | |
| dc.subject.other | Sulfonyl tris indole derivative | |
| dc.subject.other | Unclassified drug | |
| dc.subject.other | Antineoplastic activity | |
| dc.subject.other | Antiproliferative activity | |
| dc.subject.other | Article | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Drug screening | |
| dc.subject.other | Drug synthesis | |
| dc.subject.other | Human | |
| dc.subject.other | Human cell | |
| dc.subject.other | IC 50 | |
| dc.subject.other | Priority journal | |
| dc.subject.other | Structure activity relation | |
| dc.subject.other | Antineoplastic Agents | |
| dc.subject.other | Arylsulfonates | |
| dc.subject.other | Carcinoma, Hepatocellular | |
| dc.subject.other | Cell Line, Tumor | |
| dc.subject.other | Cell Proliferation | |
| dc.subject.other | Cholangiocarcinoma | |
| dc.subject.other | Drug Screening Assays, Antitumor | |
| dc.subject.other | Hep G2 Cells | |
| dc.subject.other | Humans | |
| dc.subject.other | Indoles | |
| dc.subject.other | Liver Neoplasms | |
| dc.subject.other | Lung Neoplasms | |
| dc.subject.other | Neoplasms | |
| dc.subject.other | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
| dc.subject.other | Structure-Activity Relationship | |
| dc.subject.other | Sulfonamides | |
| dc.title | Synthesis and structure-activity relationship of mono-indole-, bis-indole-, and tris-indole-based sulfonamides as potential anticancer agents | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880829458&doi=10.1007%2fs11030-013-9457-7&partnerID=40&md5=f954dc5a8a04272b455f3e4346568f8a |
